Daré Bioscience (NASDAQ:DARE – Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.02, Zacks reports. The company had revenue of ($0.06) million for the quarter, compared to analysts’ expectations of $1.00 million.
Daré Bioscience Stock Up 1.4 %
DARE stock opened at $2.92 on Tuesday. The stock has a market cap of $25.40 million, a price-to-earnings ratio of -4.92 and a beta of 1.38. Daré Bioscience has a 52-week low of $2.67 and a 52-week high of $7.56. The business has a fifty day moving average of $3.06 and a two-hundred day moving average of $3.29.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Daré Bioscience in a research note on Tuesday.
About Daré Bioscience
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
See Also
- Five stocks we like better than Daré Bioscience
- Election Stocks: How Elections Affect the Stock Market
- Berkshire Hathaway Gains Defy Stock Market Slump
- Growth Stocks: What They Are, Examples and How to Invest
- Palantir Stock Builds Momentum on New Partnership
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Tech Sell-Off Makes Microsoft Stock Look Like a Steal
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
